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Abstract Proteins that inhibitglycoprotein (GP) IIb/IIIamediated 
platelet aggregation have been purified from the venom of 
two snake species. A small platelet aggregation inhibi- 
tor (pl.AI), multisquamatin (Mr=5,700), was purified from 
Echis multisquamatus venom by hydrophobic interaction 
HPLC and two steps on Cl8 reverse phase HPLC. A larger 
pl.AI, contortrostatin (Mr=15,000), was purified by a 
similar HPLC procedure from the venom of Agkistrodon con- 
tortrix contortrix. Both pl.AIs inhibit ADP-induced hu- 
man, canine and rabbit platelet aggregation using plate- 
let rich plasma (PRP). Multisquamatin has an IC5U of 97 
nM, 281 nM and 333 nM for human, canine and rabbrt PRP, 
respectively. Contortrostatin has an IC of 49 nM, 120 
nM and 1,150 nM for human, canine an 561 
respectively. In a competitive binding 
rabbit lSf;L 
assay using 
7E3 (a monoclonal antibody to GPIIb/IIIa that inhibits 
platelet aggregation) bothcontortrostatin andmultisqua- 
matin demonstrated GPIIb/IIIa specific binding to human 
and canine platelets. The IC 
z" 
for contortrostatin 
displacement of 7E3 binding to uman and canine GPIIb- 
/IIIa is 27 nM and 16 nM, respectively and for multisqua- 
matin it is 3 nM and 63 nM, respectively. Our results 
indicate that both pl.AIs inhibit platelet aggregation by 
binding with high affinity to GPIIb/IIIa. 
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Platelets serve an important role in mediating coronary artery 
thrombosis and rethrombosis in the genesis of acute myocardial 
infarction (1). Thus inhibition of platelet aggregation may 
provide an effective adjunctive approach for prevention of coronary 
artery reocclusion after successful thrombolytic therapy. Platelet 
aggregation involves the interaction of the platelet membrane 
glycoprotein (GP) IIb/IIIa receptor with plasma fibrinogen. 
GPIIb/IIIa belongs to the superfamily of integrin cell surface 
receptors (2). Integrins are heterodimers composed of a and Q 
subunits that are noncovalently associated. They have been shown 
to be involved in cell-cell and cell-substratum interactions (3). 
It has been shown that both the a and the fl subunits are required 
for fibrinogen binding (3). Integrins serve as receptors for 
extracellular matrix proteins such as fibronectin, fibrinogen, 
vitronectin, collagen and laminin (3). Some of these interactions 
have been shown to be mediated via an Arg-Gly-Asp (RGD) sequence 
present in the matrix proteins (3). For platelet aggregation an 
RGD sequence present in fibrinogen is essential for the interaction 
with GPIIb/IIIa (3). 
A number of disintegrins or platelet aggregation inhibitors 
(pl.AIs) have been isolated from snake venoms (4-9). They are 
small proteins, rich in disulfide bonds and contain the RGD 
sequence. Recently pl.AIs have been characterized with respect to 
the amino acid sequence around the RGD site (10). The RGD sequence 
is present in all known pl.AIs except barbourin, the pl.AI purified 
from Sisturus m. barbouri, which has a Lys-Arg-Asp (KGD) sequence 
instead of RGD and seems to be highly GPIIb/IIIa specific (8). 
In this communication, we describe two pl.AIs, contortrostatin and 
multisqamatin, that have been purified from different snake venoms. 
Contortrostatin was purified from the venom of Agkistrodon 
contortrix contortrix (Southern copperhead) and multisquamatin was 
purified from the venom of Echis multisquamatus. We have studied 
the inhibitory activity of both proteins on platelets obtained from 
humans and two animal species. We have also studied the ability of 
these pl.AIs to compete for binding sites with a monoclonal 
antibody (7E3) directed to GPIIb/IIIa (11). In this report we 
present evidence indicating that contortrostatin and multisquamatin 
inhibit platelet aggregation by binding to the integrin receptor, 
GPIIb/IIIa. 
MATERIALS AND METHODS 
Materials: 
Lyophilized venom from Agkistrodon contortrix contortrix was 
obtained from Biotoxins, Inc., St. Cloud, FL; venom from Echis 
multisquamatus was obtained from Latoxan, Rosans, France. All 
chemicals were of the highest grade available. Pierce protein 
assay kit using bicinchoninic acid was employed to determine 
protein concentrations (12). 
Hioh Performance Liauid Chromatosraphv IHPLC): 
For hydrophobic interaction (HIC)-HPLC a Perkin Elmer 410 LC pump 
was employed with a LC-95 UV/VIS detector and for reverse phase 
HPLC a Spectra Physics LC 8810 pump was employed with an SP 8450 
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UV/VIS detector. Absorbance for HIC-HPLC was monitored at 280 nm 
and for RP-HPLC at 215 nm. A polypropyl aspartamide (250 x 21 mm) 
column (Poly LC, Columbia, MD) was used for hydrophobic interaction 
HPLC. Cl8 (218TP54 and 218TP510) columns were used for reverse 
phase (RP) HPLC (Vydac, Hesperia, CA). 
Purification of contortrostatin. the platelet assresation inhibitor 
from Ackistrodon contortrix contortrix venom: 
Contortrostatin was purified fromAgkistrodon contortrix contortrix 
(Southern copperhead) venom using a three step HPLC procedure. For 
the first step of purification crude venom (1 g) was dissolved in 
0.1 M phosphate buffer containing 1 M ammonium sulphate, pH 6.8 
(buffer A) and applied to the polypropyl aspartamide HIC-HPLC 
column. Elution was achieved as follows: 50 minutes isocratically 
with 100% buffer A; a linear gradient for 90 minutes to 0.1 M 
phosphate, pH 6.8 (buffer B); 40 minutes isocratic at 100% buffer 
B. Fractions of 10 ml were collected in a Pharmacia Frac 100 
fraction collector at 4'C using a flow rate of 5 ml/min. Fractions 
containing pl.AI activity were pooled and concentrated by ultra- 
filtration using an Amicon stir cell with a YM3 membrane. Further 
purification was achieved by Cl8 RP-HPLC. The Cl8 column (218TP510) 
was equilibrated with 95% of 0.1% TFA in water (solvent A) and 5% 
of 80% acetonitrile in 0.1% TFA in water (solvent B). Elution was 
achieved as follows: isocratic at 95% solvent A and 5% solvent B 
for 10 minutes; a linear gradient to 40% solvent B in 65 minutes; 
linear gradient to 100% solvent B in 20 minutes; isocratic at 100% 
solvent B for 25 minutes. Fractions were collected manually every 
minute at a flow rate of 7 ml/minute. Fractions containing pl.AI 
activity were pooled and rerun on the same Cl8 RP-HPLC column using 
a shallower gradient. Elution was achieved as follows: isocratic 
at 80% solvent A and 20% solvent B for 20 minutes; a linear 
gradient to 30% solvent B over 90 minutes; and a 25 minute linear 
gradient to 100% solvent B. 
Purification of multisauamatin, the platelet assresation inhibitor 
from Echis multisquamatus venom: 
Multisquamatin was purified from 1 gram of Echis multisquamatus 
venom by a three step HPLC procedure. In the first step crude 
venom (1 g) was treated as Agkistrodon contortrix contortrix venom 
and applied to the HIC-HPLC column. Elution conditions were 
identical to the first step employed for the purification of 
contortrostatin. Pl.AI activity coeluted with platelet aggregatory 
activity in the HIC flow through. Cl8 RP-HPLC was employed to 
separate platelet inhibitory activity from platelet aggregatory 
activity. Fractions from the HIC flow through were pooled and 
concentrated using an Amicon stir cell with a YM3 membrane and 
subsequently applied to a Cl8 RP-HPLC column (218TP510). Elution 
was achieved as follows: 10 minute isocratic at 95% solvent A and 
5% solvent B; a linear gradient to 30% solvent B over 110 minutes; 
and a linear gradient from 30% to 100% solvent B over 30 minutes; 
isocratic at 100% solvent B for 30 minutes. Fractions of 10.5 ml 
were collected at a flow rate of 7 ml/minute at 4OC. Active 
fractions were pooled, concentrated using a Savant Rotovac, and 
rerun on the same Cl8 RP-HPLC column. Elution was achieved as 
follows: 10 minute isocratic at 95% solvent A and 5% solvent B; a 
linear gradient to 30% solvent B over 80 minutes; a linear gradient 
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from 30% to 100% solvent B over 10 minutes; 
solvent B for 10 minutes. The peak containing 
collected manually. 
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isocratic at 100% 
pl.AI activity was 
Assav of nlatelet assresation inhibitorv activitv: 
Column fractions obtained during purification were assayed for 
pl.AI activity using fresh human platelet rich plasma (PRP) 
prepared from blood obtained from human volunteers who had no 
medication for at least two weeks. Blood (36 ml) was drawn into 4 
ml of 0.1 M citrate and centrifuged at 150 x g for 20 minutes. The 
supernatant, PRP, was removed and the remaining blood was 
centrifuged at 10,000 RPM to obtain platelet poor plasma (PPP). 
Platelet counts were adjusted to 250,000 platelets/+ using a 
Coulter counter. A Bio-Data one channel aggregometer and a Helena 
four channel aggregometer were used to monitor platelet 
aggregation. Inhibition of ADP-induced platelet aggregation was 
monitored at 37OC by adding venom fractions one minute prior to the 
addition of ADP (lo-20 PM final concentration). Fractions exhibi- 
ting pl.AI activity were pooled and further purified. Rabbit and 
canine PRP was prepared by the same procedure and used in the 
studies described below. 
SDS-nolvacrvlamide se1 electroDhoresis (SDS-PAGE): 
A Tris-Tricine 16.5% gel was used according to the protocol of 
Schagger and von Jagow under reducing and nonreducing conditions 
(13). The gel was run using a Biorad minigel system and stained 
with silver (14) or Coomassie blue R250. 
Measurement of GPIIb/IIIa snecific bindinq: 
Measurement of contortrostatin and multisquamatin binding to 
platelet GPIIb/IIIa receptor was carried out using PRP prepared 
from blood obtained from human volunteers or male mongrel dogs. PRP 
was prepared as described above and the platelet count was 
determined with a H-10 cell counter (Texas International 
Laboratories, Inc., Houston, TX). PRP (180 ~1) was incubated with 
20 ~1 of varying concentrations of either contortrostat$. or 
multisquamatin at room temperature. Radiolabelled antibody ( 51- 
7E3 IgG, 20 ~1, 18 mg/ml, 80,000 cpm), specific for GPIIb/IIIa, was 
then added and the mixture incubated for 30 minutes. To establish 
equilibrium binding, 50 7~1 aliquots of the binding assay mixture 
were layered over 200 7.~1 of 30% sucrose in 0.4 ml microcentrifuge 
tubes and spun at 10,000 RPM for 4 minutes in a swinging bucket 
rotor to separate platelet-bound antibody from free antibody. The 
pellet and the supernatant were separated and counted in a Pa 
Minaxi 5000 series gamma counter. The number of molecules of F&;d 
7E3 bound per platelet in the presence and absence of pl.AI was 
calculated by using the following formula: 
f4) x 0.9 nc 7E3 x 3.76 x 1012 molecules 7E3/nq 
(5) 
where: 
1 = Pellet 2 = Supernatant 3 = Total CPM 
counts counts (1) + (2) 
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4= Fraction 5 = Platelet 
bound counts per 
(l)/(3) pl x 45 pl 
RESULTS 
Purification of contortrostatin: 
Contortrostatin was purified from Southern copperhead venom using 
a three step chromatographic approach: HIC-HPLC, and two steps on 
Cl8 RP-HPLC. For the first step of purification crude venom was 
disolved in a minimal volume of HIC buffer A and applied to the 
HIC-HPLC column. Proteins were eluted by a decreasing gradient of 
ammonium sulfate and were detected at 280 nm (Fig. 1 A). Pl.AI 
activity was observed in the flow through. Fractions containing 
pl.AI activity were pooled and concentrated for the second step of 
purification. In this step pooled fractions were applied to a Cl8 
RP-HPLC column equilibrated with 0.1% TFA and 4% acetonitrile. 
Elution was achieved by an increasing gradient of acetonitrile 
(Fig. 2 A). Contortrostatin eluted at 28% acetonitrile (66 min). 
For the final step of purification, fractions containing pl.AI 
activity were applied to the Cl8 RP-HPLC column this time 
equilibrated with 0.1% TFA and 16% acetonitrile. Using a shallower 
gradient to 24% acetonitrile (Fig. 3 A), contortrostatin eluted as 
a sharp peak at 22% acetonitrile (82 min). The minor peak eluting 
just before contortrostatin also contained pl.AI activity and had 
a similar molecular weight to that of contortrostatin. Due to the 
low yield this peak was not further characterized. Yields of l-2 
mg of three step purified contortrostatin were obtained per gram of 
crude venom. 
Purification of multissuamatin: 
Multisquamatin was purified from Echis multisquamatus venom by a 
similar chromatographic approach to that used for the purification 
of contortrostatin. Crude venom was directly applied to the HIC- 
HPLC column under the same conditions used for Southern copperhead 
venom. Elution was achieved by a decreasing gradient of ammonium 
sulfate (Fig. 1 B). The major protein peak eluting in the flow 
through possessed platelet aggregating activity. This peak also 
contains pl.AI activity but it was difficult to detect due to the 
coeluting platelet aggregating activity. To confirm that the HIC 
flow through peak possessed pl.AI activity we applied aliquots to 
an analytical Cl8 RP-HPLC column (218TP54). One of the major peaks 
eluting from the Cl8 RP-HPLC column possessed pl.AI activity 
thereby indicating that the flow through peak from the HIC-HPLC 
column contains pl.AI activity. Active fractions from the HIC 
column were pooled, concentrated, and applied to the preparative 
Cl8 RP-HPLC column equilibrated with 0.1% TFA and 4% acetonitrile. 
Elution was obtained by an increasing gradient to 80% acetonitrile 
(Fig.2 B). Pl.AI activity was obtained in the major peak eluting 
at 14% acetonitrile (61 mins). In order to remove minor conta- 
minants multisquamatin was rerun on the Cl8 RP-HPLC column (Fig. 3 
B). Multisquamatin eluted at 68 min (16% acetonitrile). Yields of 
lo-11 mg of three step purified multisquamatin were obtained per 
gram of crude venom. 
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FIG. 1. 
Separation of crude venoms by HIC-HPLC. (A) Agkistrodon 
contortrix contortrix was injected onto a HIC-HPLC 
column. (B) E&is multisquamatus venom was applied to 
the HIC-HPLC column under the same conditions as used for 
Agkistrodon contortrix contortrix venom. Refer to Mate- 
rials and Methods for elution conditions. Arrows identify 
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FIG. 2. 
Cl8 RP-HPLC separation. (A) Pooled fractions from HIC- 
HPLC of Agkistrodon contortrix contortrix venom were 
applied to a Cl8 RP-HPLC column. (B) Pooled fractions 
from HIC-HPLC of Echis multisquamatus venom were applied 
to the Cl8 RP-HPLC column. Refer to Materials and Me- 
thods for elution conditions. Peaks containing pl.AI 
activity are indicated by the arrows. 
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FIG. 3. 
Final step of purification of contortrostatin and multi- 
squamatin. (A) Contortrostatin was further purified by 
rerunning on the Cl8 RP-HPLC column but with a shallower 
gradient. It eluted at 82 min (22% acetonitrile) and was 
collected manually. Multisquamatin was further purified 
by rerunning on the Cl8 column using the same gradient as 
in the second step. It eluted at 68 min (16% acetonit- 
rile) and was collected manually. Refer to Materials and 
Methods for elution conditions. Arrows indentify peaks 
containing pl.AI activity. 
SDS-PAGE analysis: 
Reducing and nonreducing SDS-PAGE were used to assess homogeneity 
and to calculate molecular mass of purified pl.AIs (Fig. 4). SDS- 
PAGE analysis of contortrostatin revealed that it has a molecular 
mass of approximately 15,000 Da under nonreducing conditions and 
5,000-7,000 Da under reducing conditions, thereby suggesting that 
it is composed of two or three subunits. Another possibility, 
although unlikely, is that the large difference in migration may be 
attrib ted to differential uptake of SDS under nonreducing and 
reducin conditions (5). Multisquamatin, on the other hand, has a '$ 
molecular mass of 6,400 Da under nonreducing conditions and 5,700 
Da under reducing conditions. Echistatin, the pl.AI purified from 
the venom of Echis carinatus (Mr=5.4 kDa) (S), exhibits a similar 
differential migration pattern to that of multisquamatin under 
reducing and nonreducing SDS-PAGE. This pattern in SDS-PAGE 
migration could be attributed to differential detergent binding 
based on structural differences under reducing and nonreducing 
conditions. 
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123456 
FIG. 4. 
SDS-PAGE of contortrostatin and multisquamatin. Lanes 1 
and 6 are low molecular weight markers: 3lkDa, carbonic 
anhydrase; 20.4/19.7kDa, soybean trypsin inhibitor 
doublet; 16.9kDa, horse heart myoglobin; 14.4, lysozyme; 
8.1 myoglobin CNBr fragment 1 (Fl); 6.2kDa, myoglobin 
(F2); and 2.5kDa, myoglobin (F3). Lanes 2 and 3 are 1 pg 
of reduced and nonreduced contortrostatin, respectively. 
Lanes 4 and 5 are 1 pg of nonreduced and reduced multi- 
squamatin, respectively. The gel was stained with Coo- 
massie blue R250. 
Inhibition of platelet assresation: 
Contortrostatin and multisquamatin inhibit ADP-induced platelet 
aggregation in human, canine, and rabbit PRPs (Fig. 5). Contor- 
trostatin (0.73 pg/ml) and multisquamatin (0.55 pg/ml) inhibited 10 
PM ADP-induced human platelet aggregation by 50% (IC5 
for 20 PM ADP-induced canine platelet aggregation is P 
). The IC50 
.8 pg/ml for 
contortrostatin and 1.6 pg/ml for multisquamatin. Interestingly, 
the IC 
5V 
for contortrostatin mediated inhibition of rabbit platelet 
aggrega ion is considerably higher. The IC for 20 PM ADP-induced 
rabbit platelet aggregation is 17.3 pg/ml ?& contortrostatin, but 
only 1.9 pg/ml for multisquamatin. 
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FIG. 5. 
for contortrostatin inhibition 
(*) Determkkk?a~~ :&it platelet aggregation. Empty of human, 
circles represent human PRP, solid circles represent 
canine PRP, and empty triangles represent rabbit PRP. 
Varying concentrations of controtrostatin were preincu- 
bated with PRP prior to the addition of ADP. Contortros- 
tatin has an IC50 of 0.73 pg/ml, 1.8 pg/ml and 17.3 pg/ml 
for inhibition of human, canine and rabbit platelet ag- 
gregation, respectively. (B) Determination of IC50 for 
multisquamatin inhibition of human, canine and rabbit 
platelet aggregation. The symbols are the same as for 
contortrostatin. Varying concentrations of multisqua- 
matin were preincubated with PRP as for contortrostatin. 
Multisquamatin has an IC50 of 0.55 pg/ml, 1.6 pg/ml and 
1.9 pg/ml for human, canine and rabbit platelet aggrega- 
tion, respectively. Each point represents the average of 
three determinations. 
Determination of GPIIb/IIIa specific bindins of pl.AIs usins the 
monoclonal antibodv.7E3: 
The murine monoclonal antibody, 7E3, is a potent inhibitor of human 
and canine platelet aggregation (11). To determine if contor- 
trostatin and multisquamatin inhibit platelet aggregation by 
binding to GPIIb/IIIa, we employed competitive binding studies 
using 7E3. These studies demonstrated specific platelet GPIIb/IIIa 
receptor binding for the two pl.AIs with both human and canine 
platelets (Fig. 6). The concentration of contortrostatin to 
inhibit 50% of 7E3 binding to human GPIIb/IIIa (IC50) is 0.4 pg/ml. 
Multisquamatin has an IC5 for human GPIIb/IIIa of 0.018 pg/ml. 
:,":Ib;;?n 
for contortros atin P and multisquamatin for canine 
a is 0.24 yg/ml and 0.36 pg/ml, respectively. These 
studies indicate that both contortrostatin and multisquamatin 
inhibit platelet aggregation by binding to GPIIb/IIIa. 
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(A) Binding of contortrostatin and multisquamatin to 
human GPIIb/IIIa in the presence of a fixed saturating 
concentration of 7E3. Solid line with solid triangle 
represents contortrostatin and dotted line with solid 
circle represents multisquamatin. The IC50 for contor- 
trostatin displacement of 7E3 is 0.4 pg/ml and for 
multisquamatin it is 0.018 pg/ml. (B) Binding of contor- 
trostatin and multisquamatin to canine platelet GPIIb- 
/IIIa in the presence of a fixed saturating concentration 
of 7E3. The symbols are as in A. The IC 
I0 
for contor- 
trostatin displacement of 7E3 is 0.25 pg/m and for mul- 
tisquamatin it is 0.36 pg/ml. Refer to Materials and Me- 
thods for a detailed description. Each point represents 
the average of at least three determinations. 
DISCUSSION 
Recently platelet aggregation inhibitors have been purified from 
venoms of snakes of the Crotalidae and Viperidea families (4-10). 
The first pl.AI to be reported was trigramin from Trimeresurus 
gramineus venom (4). This pl.AI was shown to bind to the GPIIb/IIIa 
complex on the platelet surface (4). All pl.AIs purified thus far, 
with the exception of barbourin (8), possess the RGD sequence. 
This sequence motif has been implicated as being involved in the 
inhibition of integrin mediated interactions (1). Therefore, a 
number of investigators have examined the efficacy of linear and 
cyclic RGD peptides (15, 16) or cyclic KGD peptides (17) as 
antiplatelet agents. However, there appears to be increasing 
evidence that pl.AIs may have unique surface geometry which 
facilitates interactions with integrins by mechanisms other than 
those solely based on the RGD site. Recently it has been reported 
Vol. 73, No. 1 VENOM DISINTEGRINS 49 
that some snake venom metalloproteinases, which have no structural 
resemblance to mammalian matrix-degrading metalloproteinases, con- 
tain a domain which bears a striking resemblance to the pl.AI 
sequence (18-21). Although the pl.AI domain is devoid of the RGD 
sequence in at least one of the metalloproteinases (18), the 
proteinase is a potent inhibitor of ADP- and collagen-induced 
platelet aggregation. Furthermore, the finding that a mutated, 
chemically synthesized pl.AI derivative of echistatin (alanine 
substituted for arginine in the RGD sequence) still possessed some 
biological activity (22), suggests that other regions in the 
protein may be involved in binding and that there may be some 
flexibilty in the RGD binding site. The synthetic RGD peptides, 
due to their small size, do not possess the molecular topography of 
the pl.AIs and, therefore, cannot interact with the multiplicity of 
mechanisms used by pl.AIs. 
In view of the potential clinical use of pl.AIs as antithrombotic 
agents we have purified two pl.AIs, contortrostatin and multi- 
squamatin, from Agkistrodon contortrix contortrix and Echis 
multisquamatus venoms, respectively. Both contortrostatin and 
multisquamatin are potent inhibitors of human, rabbit, and canine 
platelet aggregation. Interestingly, studies in collaboration with 
Dr. Joan Brugge and Edwin A. Clark, at Ariad Pharmaceuticals Inc., 
Cambridge, MA, have shown that contortrostatin does not inhibit 
platelet release reactions (unpublished results). The partial 
amino acid sequence of contortrostatin shows significant identity 
with applaggin (6). However, there appears to be an interesting 
difference in that the sequence for contortrostatin begins nine 
amino acid residues downstream from the applaggin start site 
(unpublished results). Presumably the amino terminal deletion has 
effect pl.AI activity ’ the 
z&tortrostat% and applaggin are v%yzimilar (6). 
IC50 values for 
Multisquamatin appears to be similar to echistatin (5) based on the 
amino terminal sequence. However, the amino terminus of 
multisquamatin appears to start three amino acids upstream from the 
echistatin start site (unpublished results). The yield for 
multisquamatin (lo-11 mg per gram of crude venom) is to our 
knowledge the highest yield of any pl.AI reported thus far. It 
appears that multisquamatin and contortrostatin are not very 
hydrophobic because they do not bind to the HIC-HPLC column. 
Furthermore, they elute early in the Cl8 RP-HPLC gradient which 
separates proteins based on their hydrophobicity (23). This is 
supported by their amino acid composition which is low in 
hydrophobic amino acids (unpublished results). 
Several lines of evidence indicate that contortrostatin and 
multisquamatin inhibit platelet aggregation by binding specifically 
to the GPIIb/IIIa integrin receptor. Thus, in a fibrinogen- 
GPIIb/IIIa ELISA (24), in which the extent of purified GPIIb/IIIa 
bound to immobilized fibrinogen can be quantitated, both 
multisquamatin and contortrostatin effectively block GPIIb/IIIa 
binding (data not shown). Addititonally, the partial amino acid 
sequences of both pl.AIs indicate considerable identity with other 
snake venom pl.AIs which are known to bind to GPIIb/IIIa. Finally, 
contortrostatin and multisquamatin block 7E3 binding to GPIIb/IIIa 
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(Fig. 6). 7E3 is a murine monoclonal antibody that specifically 
binds to GPIIb/IIIa, thereby inhibiting platelet aggregation (11). 
In the presence of low concentrations of either contortrostatin or 
multisquamatin 7E3 binding to platelets was significantly inhibited 
(Fig. 6). 
An interesting observation is the relatively high IC58 for inhibi- 
tion of rabbit platelet aggregation by contortrostatin. The IC 
of 17.3 pg/ml is considerably higher than its IC 
and 1.8 pg/ml for inhibition of human and canine p 5_O 
of 0.73 pg/m 5P 
atelet aggrega- 
tion, respectively. However the IC 
inhibition of human, canine and rab it platelet aggregation are z" 
values for multisquamatin 
very similar. This apparent difference raises two possible 
questions. First, does contortrostatin have a different mechanism 
of inhibition of platelet aggregation than multisquamatin? Second, 
is the rabbit GPIIb/IIIa different than GPIIb/IIIa present on 
human and canine platelets? Further study into the mechanisms 
involved in contortrostatin and multisquamatin mediated inhibition 
could provide more insight into the mechanistic differences between 
rabbit GPIIb/IIIa and its counterpart in human and canine 
platelets. 
Two snake venom pl.AIs, kistrin (9) and bitistatin (25), have 
demonstrated a potential role as antithrombotic agents for use in 
thrombolytic therapy by enhancing and sustaining arterial 
thrombolysis in conjunction with recombinant tissue plasminogen 
activator. Based on the low IC50 values of contortrostatin we have 
tested its in vivo efficacy as an antithrombotic agent. Using a 
canine carotid reoccluding arterial thrombosis model, preliminary 
results with contortrostatin have been promising. In conjunction 
with APSAC contortrostatin efficiently sustains opening of the 
carotid artery, whereas APSAC alone is unable to prevent the rapid 
reocclusion of the carotid artery. Further in vivo characteriza- 
tion of both contortrostatin and multisquamatin is in progress. 
Based on the experiments described above both contortrostatin and 
multisquamatin have been shown to be potent inhibitors of 
GPIIb/IIIa mediated platelet aggregation. 
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